Thailand preparing to limit exports of its COVID-19 vaccine

Wednesday, July 14, 2021 | Chalida Ekvittayavechnukul, Associated Press


A health worker administers a dose of the AstraZeneca COVID-19 vaccine to a woman at Central Vaccination Center in Bangkok, Thailand, Wednesday, July 14, 2021. Health authorities in Thailand said Wednesday they will seek to put limits on the export of locally produced AstraZeneca vaccine, as the country’s supplies of COVID-19 vaccines are falling short of what is needed for its own population. (AP Photo/Sakchai Lalit)

BANGKOK (AP) — Health authorities in Thailand said Wednesday they will seek to impose limits on exports of locally produced AstraZeneca coronavirus vaccine because the country doesn't have enough for its own needs.

The proposal comes as new cases and deaths are rapidly increasing along with the spread of the more contagious delta variant of the virus, straining hospital facilities and threatening to set back a recovery of the country's battered economy.

Limiting exports will pose a problem for Southeast Asian countries that have signed contracts to buy Thai-produced vaccines, though some may be able to obtain supplies elsewhere.

Dr. Nakorn Premsri, director of the National Vaccine Institute, said its vaccine committee agreed in principle to issue an order temporarily limiting exports, but did not give any details. The order would be issued by designating it a matter of national security.

A company owned by Thailand's king, Siam BioScience, was supposed to supply the country with 10 million doses of AstraZeneva vaccine a month, but acknowledged earlier this month that it can provide only 5 million to 6 million doses.

Siam BioScience was awarded a license by AstraZeneca to be a regional production hub supplying eight other countries despite having no experience in manufacturing vaccines.

Several countries have reported being told by Siam BioScience that they would not receive the contracted vaccines on time, lending weight to speculation that the Thai factory was having production problems. Nakorn said Wednesday that AstraZeneca is supposed to deliver at least one-third of its monthly production at the Thai facility to Thailand's government.

Thailand launched a mass vaccination campaign only in early June, and critics accuse the government of Prime Minister Prayuth Chan-ocha of failing to secure adequate and timely supplies of vaccines. Its plan at the beginning of the year would have allowed only about half the 69 million population to be vaccinated this year, and most of them in the second half of the year.

Thailand has so far administered 13.23 million vaccine doses. Around 9.88 million people, or about 14.3% of its 69 million population, have received at least one dose.

The government is now targeting 100 million doses by the end of the year, enough to vaccinate 50 million people, just over 70% of the population.

Thailand has been negotiating with other producers to make up for the vaccine shortfall. So far, it has only used vaccines from AstraZeneca and China’s Sinovac and Sinopharm, although the government says it has agreements to also buy from Pfizer and Johnson & Johnson.

Health officials announced Monday that medical workers who received two doses of the Sinovac vaccine will be given booster shots of the AstraZeneca vaccine. They made the decision after a nurse who received two doses of Sinovac in May died Saturday after contracting COVID-19.

The head of the Thai Red Cross Emerging Infectious Diseases Health Science Center, Dr. Thiravat Hemachudha, said last week that a study he helped conduct found that Sinovac was less effective at fighting the delta variant, and that a booster dose of AstraZeneca would increase its efficacy.

Other Thais who have received only one dose of Sinovac will be able to get AstraZeneca for their second dose, Health Minister Anutin Charnvirakul said.

A nighttime curfew and other new coronavirus restrictions came into effect Monday in Bangkok and nearby provinces and in the country’s four southernmost provinces, which have been the most severely affected by the current virus surge.

The sharp rise in cases has caused a severe shortage of hospital beds for COVID-19 patients, prompting the authorities to allow patients to isolate at home and in community centers, and giving them access to antigen test kits that were previously limited to the medical community.

India also imposed limits on vaccine exports when it was hit by a devastating coronavirus outbreak earlier this year.

Should you invest $1,000 in Pfizer right now?

Before you consider Pfizer, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.

While Pfizer currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 


Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Johnson & Johnson (JNJ)2.6$173.36-0.6%2.45%26.07Buy$190.38
Pfizer (PFE)2.8$45.19-1.1%3.45%19.39Hold$43.08
Compare These Stocks  Add These Stocks to My Watchlist 

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.